(12/09/2019) Inotrem announces €39 Million Series B Financing to Develop First- In-Class Immunology Therapeutics.

Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes, announced today a €39 million Series B financing led by Morningside Ventures, joined by Invus with participation from existing investors Andera Partners, Sofinnova Partners and BiomedInvest.

Press realease : 190912-inotrem-raises-39m-in-series-b-financing




Nous contacter

We're not around right now. But you can send us an email and we'll get back to you, asap.